Last reviewed · How we verify
Ibandronate (Bondronat)
Ibandronate (Bondronat) is a Bisphosphonate Small molecule drug developed by Chinese Society of Lung Cancer. It is currently FDA-approved for Bone metastases in breast cancer, Osteoporosis prevention and treatment, Hypercalcemia of malignancy. Also known as: no other names.
Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.
Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Bone metastases in breast cancer, Osteoporosis prevention and treatment, Hypercalcemia of malignancy.
At a glance
| Generic name | Ibandronate (Bondronat) |
|---|---|
| Also known as | no other names |
| Sponsor | Chinese Society of Lung Cancer |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase; hydroxyapatite in bone |
| Modality | Small molecule |
| Therapeutic area | Oncology; Bone metabolism |
| Phase | FDA-approved |
Mechanism of action
Bisphosphonates like ibandronate are taken up by osteoclasts during bone resorption and inhibit the mevalonate pathway, leading to osteoclast apoptosis and reduced bone turnover. This mechanism makes it effective for conditions characterized by excessive bone loss, including osteoporosis and bone metastases in cancer patients.
Approved indications
- Bone metastases in breast cancer
- Osteoporosis prevention and treatment
- Hypercalcemia of malignancy
Common side effects
- Osteonecrosis of the jaw
- Atypical femoral fractures
- Musculoskeletal pain
- Nausea
- Renal impairment
Key clinical trials
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases (PHASE2)
- Denosumab Safety Assessment in Multiple Observational Databases
- Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate (PHASE2)
- Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America
- Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy. (NA)
- Post-fracture Medication and Mortality
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibandronate (Bondronat) CI brief — competitive landscape report
- Ibandronate (Bondronat) updates RSS · CI watch RSS
- Chinese Society of Lung Cancer portfolio CI
Frequently asked questions about Ibandronate (Bondronat)
What is Ibandronate (Bondronat)?
How does Ibandronate (Bondronat) work?
What is Ibandronate (Bondronat) used for?
Who makes Ibandronate (Bondronat)?
Is Ibandronate (Bondronat) also known as anything else?
What drug class is Ibandronate (Bondronat) in?
What development phase is Ibandronate (Bondronat) in?
What are the side effects of Ibandronate (Bondronat)?
What does Ibandronate (Bondronat) target?
Related
- Drug class: All Bisphosphonate drugs
- Target: All drugs targeting Farnesyl pyrophosphate synthase; hydroxyapatite in bone
- Manufacturer: Chinese Society of Lung Cancer — full pipeline
- Therapeutic area: All drugs in Oncology; Bone metabolism
- Indication: Drugs for Bone metastases in breast cancer
- Indication: Drugs for Osteoporosis prevention and treatment
- Indication: Drugs for Hypercalcemia of malignancy
- Also known as: no other names
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing